Study on preparation and characterization of poly(β-malic-acid)-doxorubicin/do-cetaxel nanoconjugate

Zhe YU,Qing ZHOU,Youbei QIAO,Songyan GUO,Yu ZHANG,Hong WU

DOI: https://doi.org/10.3969/j.issn.1004-2407.2018.03.020

2018-01-01

Abstract:Objective To synthesize polymer-drug conjugate based on poly(β-malic acid)(PMLA)bearing simultaneously doxorubi-cin(DOX)and docetaxel(DTX)and study the synergistic effect.Methods The method simultaneously conjugated DOX and DTX to mPEG-PMLA was a"one pot"method and the drug loading rates were determined by HPLC,simulation of drug release in vivo by dynamic dialysis.Dynamic dialysis was used to simulate drug release in vitro.MDA-MB-231 cells were used to study the syner-gistic effects and cellular uptake.Results The content of DOX in PMLA-DOX/DTX was 21.5% ± 1.2% and DTX was 11.03% ± 1.51%.In vitro cytotoxicity assay(human breast cancer cell,MDA-MB-231),when the drug ratio was 10:1,the synergistic effect was better.Dual drug-loaded conjugates could be easier to be internalized by the cells than free drugs.Conclusion PMLA delivered the chemotherapeutic drugs DOX and DTX simultaneously with high drug loading,which could tolerate the side effects with the ef-ficient anti-tumor effect to make it a good candidate of nanocarrier.